*19% of DreamMapper users used their therapy 100% of the nights over 90-days versus 12% for the Standard Care users, a 58.33% increase.
In a retrospective review conducted by Philips Respironics of the EncoreAnywhere database (see DreamMapper whitepaper) that compared DreamMapper patients (n=85,077) to users who did not use it (n=87,602).
**46% 90-day adherence rate for DreamMapper patients versus 12% for the Standard Care group, a 283.33% increase.
In a retrospective review conducted by Philips Respironics of the EncoreAnywhere database (see DreamMapper whitepaper) of struggling patients (n= 24,378).